SET

Summary

SET (SET nuclear proto-oncogene, HGNC:10760) is a protein-coding gene on chromosome 9q34.11, encoding Protein SET (Q01105). Multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone chaperoning. It is a selective cancer dependency (DepMap: 11.1% of cell lines) and haploinsufficient (ClinGen: sufficient evidence).

The protein encoded by this gene inhibits acetylation of nucleosomes, especially histone H4, by histone acetylases (HAT). This inhibition is most likely accomplished by masking histone lysines from being acetylated, and the consequence is to silence HAT-dependent transcription. The encoded protein is part of a complex localized to the endoplasmic reticulum but is found in the nucleus and inhibits apoptosis following attack by cytotoxic T lymphocytes. This protein can also enhance DNA replication of the adenovirus genome. Several transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 6418 — RefSeq curated summary.

At a glance

• Gene–disease (curated): intellectual disability (Definitive, ClinGen) — +2 more curated relationships
• GWAS associations: 3
• Clinical variants (ClinVar): 125 total — 22 pathogenic, 15 likely-pathogenic
• Phenotypes (HPO): 41
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 11.1% of screened cell lines
• Dosage sensitivity (ClinGen): haploinsufficiency sufficient evidence, triplosensitivity no evidence
• MANE Select transcript: NM_003011

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10760
Approved symbol	SET
Name	SET nuclear proto-oncogene
Location	9q34.11
Locus type	gene with protein product
Status	Approved
Aliases	PHAPII, 2PP2A, IPP2A2, TAF-IBETA, IGAAD, TAF-I
Ensembl gene	ENSG00000119335
Ensembl biotype	protein_coding
OMIM	600960
Entrez	6418

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 12 protein_coding, 3 protein_coding_CDS_not_defined, 3 retained_intron, 1 nonsense_mediated_decay

ENST00000322030, ENST00000372686, ENST00000372688, ENST00000372692, ENST00000409104, ENST00000466009, ENST00000477806, ENST00000480217, ENST00000480536, ENST00000485056, ENST00000685073, ENST00000686568, ENST00000686840, ENST00000691158, ENST00000878517, ENST00000878518, ENST00000921998, ENST00000921999, ENST00000968516

RefSeq mRNA: 5 — MANE Select: NM_003011 NM_001122821, NM_001248000, NM_001248001, NM_001374326, NM_003011

CCDS: CCDS48037, CCDS59149, CCDS59150, CCDS6907

Canonical transcript exons

ENST00000322030 — 8 exons

Exon	Start	End
ENSE00001052379	128693896	128694042
ENSE00001243124	128689222	128689655
ENSE00001921819	128694641	128696396
ENSE00003488572	128693638	128693808
ENSE00003513201	128692662	128692765
ENSE00003548688	128691170	128691227
ENSE00003555536	128691858	128692000
ENSE00003597730	128692868	128692981

Expression profiles

Bgee: expression breadth ubiquitous, 295 present calls, max score 99.60.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 313.1474 / max 2545.0260, expressed in 1828 samples.

FANTOM5 promoters (14 alternative TSS)

Promoter ID	TPM avg	Samples expressed
98826	280.9729	1828
98828	7.6702	1728
98827	7.2756	1711
98820	4.5293	1108
98829	3.2502	1260
98823	3.1807	1251
98822	3.1077	832
98819	1.8259	861
98817	0.5173	247
98824	0.2088	96

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ganglionic eminence	UBERON:0004023	99.60	gold quality
endometrium epithelium	UBERON:0004811	99.59	gold quality
calcaneal tendon	UBERON:0003701	99.58	gold quality
cortical plate	UBERON:0005343	99.58	gold quality
embryo	UBERON:0000922	99.54	gold quality
ventricular zone	UBERON:0003053	99.51	gold quality
epithelium of nasopharynx	UBERON:0001951	99.21	gold quality
colonic epithelium	UBERON:0000397	99.17	gold quality
endometrium	UBERON:0001295	99.17	gold quality
germinal epithelium of ovary	UBERON:0001304	99.16	gold quality
palpebral conjunctiva	UBERON:0001812	99.15	gold quality
lymph node	UBERON:0000029	99.13	gold quality
cranial nerve II	UBERON:0000941	99.10	gold quality
parietal pleura	UBERON:0002400	99.08	gold quality
medial globus pallidus	UBERON:0002477	99.07	gold quality
corpus callosum	UBERON:0002336	99.06	gold quality
tonsil	UBERON:0002372	99.03	gold quality
islet of Langerhans	UBERON:0000006	99.02	gold quality
pleura	UBERON:0000977	98.96	gold quality
vermiform appendix	UBERON:0001154	98.93	gold quality
upper arm skin	UBERON:0004263	98.93	gold quality
monocyte	CL:0000576	98.91	gold quality
smooth muscle tissue	UBERON:0001135	98.90	gold quality
globus pallidus	UBERON:0001875	98.90	gold quality
mononuclear cell	CL:0000842	98.87	gold quality
leukocyte	CL:0000738	98.86	gold quality
caecum	UBERON:0001153	98.86	gold quality
visceral pleura	UBERON:0002401	98.86	gold quality
rectum	UBERON:0001052	98.84	gold quality
gall bladder	UBERON:0002110	98.84	gold quality

Single-cell (SCXA)

Detected in 19 experiment(s), a significant marker in 7.

Experiment	Marker?	Max mean expression
E-GEOD-89232	yes	6280.66
E-GEOD-111727	yes	1449.83
E-MTAB-10042	yes	11.22
E-CURD-122	yes	10.53
E-MTAB-10553	yes	7.20
E-MTAB-9801	yes	6.39
E-MTAB-6379	no	4913.79
E-MTAB-10018	no	2639.83
E-MTAB-9689	no	2231.31
E-MTAB-8271	no	2035.38
E-HCAD-13	no	1456.09
E-MTAB-8205	no	1379.21
E-MTAB-9154	no	1246.55
E-MTAB-5061	no	1193.80
E-MTAB-6108	no	1034.54

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): KMT2A, SERTAD1, SPI1, ZNF331

miRNA regulators (miRDB)

155 targeting SET, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4282	99.99	75.36	6408
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-3912-5P	99.95	66.11	925
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163

Functional genomics

ClinGen dosage: haploinsufficiency 3 (sufficient evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map DepMap (CRISPR cell-line fitness): dependent in 11.1% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• Our detailed characterization showed that the SET protein formed a complex with Cdk5/p35(nck5a) through its binding to p35(nck5a). (PMID:11741927)
• HMG2 interacts with the nucleosome assembly protein SET and is a target of the cytotoxic T-lymphocyte protease granzyme A. (PMID:11909973)
• role in inhibiting active demethylation of DNA, integrating DNA methylation and transcriptional silencing (PMID:11978794)
• SET protein regulates G(2)/M transition by modulating cyclin B-CDK1 activity. (PMID:12407107)
• this protein and Protein phosphatase 2A regulate androgen production by P450c17. (PMID:12444089)
• SET accomplishes inhibition of proliferation of U937 cells through the induction of the differentiation program, an effect that depends on the presence of its acidic domain. (PMID:14671643)
• Set/TAF-Ibeta and pp32 proteins have roles as transducers of chromatin signaling by integrating chromatin hypoacetylation and transcriptional repression (PMID:15136563)
• protein phosphatase inhibitor-2 is a bifunctional signaling protein with separate domains to inhibit PP1 and directly stimulate Aurora-A kinase (PMID:15173575)
• PTMA associates with SET and is involved in chromatin decondensation. (PMID:15556635)
• PCOTH is involved in growth and survival of prostate cancer cells thorough, in parts, the TAF-Ibeta pathway. (PMID:15930275)
• results suggest that SET is part of both IFN-gamma-mediated and stress-mediated cellular responses and that SET induces cell differentiation via calcium and MAPK/ERK pathways (PMID:15931263)
• the histone chaperone SET regulates CBP-mediated transcription (PMID:16061203)
• in BCR/ABL-transformed cells and CML blast crisis (CML-BC) progenitors, the phosphatase activity of the tumor suppressor PP2A is inhibited by the BCR/ABL-induced expression of the PP2A inhibitor SET (PMID:16286244)
• 4 out of 5 members of the SET complex aare highly expressed in invasive grade 3 epithelial ovarian tumors. (PMID:16823850)
• SET-mediated promoter hypoacetylation is a prerequisite for coactivation of the estrogen-responsive pS2 gene by PRMT1 (PMID:16861234)
• GzmK hydrolyzes the nucleosome assembly protein SET in its recombinant and native forms or in intact cells. Cleavage of SET by GzmK abrogates its nucleosome assembly activity. After GzmK loading, SET rapidly translocate into the nucleus and SET is cleaved (PMID:17008916)
• assembly of early viral chromatin requires both the association of SET/TAF-1beta and the release of protein VII. (PMID:17034827)
• Membrane targeting of SET stimulates cell migration in a Rac1-dependent manner. (PMID:17245428)
• TAF-Ialpha/CAN and TAF-Ibeta/CAN fusion transcripts are generated by chromosome 9q34 deletion in acute myeloid leukemia (PMID:17296573)
• the specific association among SET/TAF-Ibeta/INHAT, core histones, and double-stranded DNA is requisite for histone chaperone activity (PMID:17360516)
• SET and PARP1 remove DEK from chromatin to permit access by the transcription machinery. (PMID:17529993)
• Our results indicate that SET is imported into the nucleus through its association with impalpha3/impbeta, and that localization of SET is important in regulation of neuronal death. (PMID:17608644)
• Impairment of erythroid and megakaryocytic differentiation by a leukemia-associated and t(9;9)-derived fusion gene product, SET/TAF-IBeta-CAN/Nup214. (PMID:17620317)
• Data indicate that interactions between I(2)(PP2A) and WNV capsid result in increased PP2A activity. (PMID:17868381)
• SET expression is essential for suppressing protein phosphatase type 2A phosphatase activity that would otherwise limit NK cell antitumoral and/or antiinflammatory functions by impairing NK cell production of IFN-gamma (PMID:17875674)
• Set/TAF-Ibeta acts as a ligand-activated GR-responsive transcriptional repressor, while Set-Can does not retain physiologic responsiveness to ligand-bound glucocorticoid receptor. (PMID:18096310)
• SET-NUP214 binds in the promoter regions of specific HOXA genes, where it interacts with CRM1 and DOT1L, which may transcriptionally activate specific members of the HOXA cluster. (PMID:18299449)
• SET, a substrate of caspases, was cleaved by acidic cytosolic extract independent of caspase activation (PMID:18374643)
• TSPY and its X-encoded homologue interact with cyclin B but exert contrasting functions on cyclin-dependent kinase 1 activities. (PMID:18591933)
• These studies indicated that the TAF-Ialpha promoter is under the control of Sp1.(TAF-Ialpha ) (PMID:18809386)
• This procedure improved the resolution of the SET/TAF-Ibetacrystals from around 5.5 to 2.3 A without changing the crystallization conditions. (PMID:18931446)
• I2PP2A was identified in vitro and in situ as a ceramide-binding protein, which exhibits stereoisomer specificity and fatty acid chain length preference. (PMID:19028839)
• Cell lines LOUCY and MEGAL express the recently described SET-NUP214 fusion gene. (PMID:19166587)
• Lyn is downstream of Jak2, and Jak2 maintains activated Lyn kinase in CML through the SET-PP2A-Shp1 pathway. (PMID:19234487)
• Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma. (PMID:19900756)
• crystals of template-activating factor Ibeta diffracted to 2.7 A resolution and belonged to space group P4(3)2(1)2. (PMID:20693670)
• The results of this study show that the knockdown of SET/TAF-Ibeta by si-RNA induces neuronal cell differentiation, thus implicating SET/TAF-Ibeta as a negative regulator of neuronal development. (PMID:20800572)
• granzyme B gene expression and therefore human NK-cell cytotoxicity can be regulated by the PP2A-SET interplay (PMID:21156847)
• Peptide mimetics of apoE derived from its receptor binding domain residues 130-150 bind to the SET protein, which is a potent physiological inhibitor of protein phosphatase 2A (PP2A). (PMID:21289314)
• SET is an important regulator of chromosome condensation/decondensation and disruption of the MCPH1-SET interaction might be important for the pathogenesis of primary microcephaly (PMID:21515671)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
danio_rerio	setb	ENSDARG00000003920
rattus_norvegicus	Setl2	ENSRNOG00000069776

Paralogs (19): TSPY2 (ENSG00000168757), NAP1L5 (ENSG00000177432), TSPYL6 (ENSG00000178021), TSPYL5 (ENSG00000180543), TSPYL2 (ENSG00000184205), NAP1L3 (ENSG00000186310), NAP1L2 (ENSG00000186462), NAP1L1 (ENSG00000187109), TSPYL4 (ENSG00000187189), TSPYL1 (ENSG00000189241), NAP1L4 (ENSG00000205531), TSPY3 (ENSG00000228927), TSPY8 (ENSG00000229549), SETSIP (ENSG00000230667), TSPY4 (ENSG00000233803), TSPY10 (ENSG00000236424), TSPY9 (ENSG00000238074), TSPY1 (ENSG00000258992), (ENSG00000293164)

Protein

Protein identifiers

Protein SET — Q01105 (reviewed: Q01105)

Alternative names: HLA-DR-associated protein II, Inhibitor of granzyme A-activated DNase, PHAPII, Phosphatase 2A inhibitor I2PP2A, Template-activating factor I

All UniProt accessions (6): A0A0C4DFV9, A0A8I5KS71, A0A8I5KTZ2, A0A8J8YYJ1, Q01105, Q5VXV3

UniProt curated annotations — full annotation on UniProt →

Function. Multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone chaperoning. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1. In the course of cytotoxic T-lymphocyte (CTL)-induced apoptosis, GZMA cleaves SET, disrupting its binding to NME1 and releasing NME1 inhibition. Isoform 1 and isoform 2 are potent inhibitors of protein phosphatase 2A. Isoform 1 and isoform 2 inhibit EP300/CREBBP and PCAF-mediated acetylation of histones (HAT) and nucleosomes, most probably by masking the accessibility of lysines of histones to the acetylases. The predominant target for inhibition is histone H4. HAT inhibition leads to silencing of HAT-dependent transcription and prevents active demethylation of DNA. Both isoforms stimulate DNA replication of the adenovirus genome complexed with viral core proteins; however, isoform 2 specific activity is higher.

Subunit / interactions. Headphone-shaped homodimer. Isoforms 1 and 2 interact directly with each other and with ANP32A within the tripartite INHAT (inhibitor of acetyltransferases) complex. Isoform 1 and isoform 2 interact also with histones. Isoform 2 is a component of the SET complex, composed of at least ANP32A, APEX1, HMGB2, NME1, SET and TREX1, but not NME2 or TREX2. Within this complex, directly interacts with ANP32A, NME1, HMGB2 and TREX1; the interaction with ANP32A is enhanced after cleavage. Interacts with APBB1, CHTOP, SETBP1, SGO1. (Microbial infection) Interacts with herpes simplex virus 1 VP22.

Subcellular location. Cytoplasm. Cytosol. Endoplasmic reticulum. Nucleus. Nucleoplasm.

Tissue specificity. Widely expressed. Low levels in quiescent cells during serum starvation, contact inhibition or differentiation. Highly expressed in Wilms’ tumor.

Post-translational modifications. Isoform 2 is phosphorylated on Ser-15 and Ser-24. Isoform 2 is acetylated on Lys-11. Some glutamate residues are glycylated by TTLL8. This modification occurs exclusively on glutamate residues and results in a glycine chain on the gamma-carboxyl group. N-terminus of isoform 1 is methylated by METTL11A/NTM1. Mainly trimethylated. Cleaved after Lys-176 by GZMA. The cleavage inhibits its nucleosome assembly activity and disrupts the inhibition on NME1.

Disease relevance. A chromosomal aberration involving SET is found in some cases of acute undifferentiated leukemia (AUL). Translocation t(6;9)(q21;q34.1) with NUP214/CAN. Intellectual developmental disorder, autosomal dominant 58 (MRD58) [MIM:618106] A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD58 patients show delayed development, intellectual disability, language delay and speech impairment. Some patients have motor delay or incoordination, and minor dysmorphic features. The disease is caused by variants affecting the gene represented in this entry.

Domain organisation. A long alpha helix in the N-terminus mediates dimerization, while the earmuff domain is responsible for core histone and dsDNA binding. The C-terminal acidic domain mediates the inhibition of histone acetyltransferases and is required for the DNA replication stimulatory activity.

Similarity. Belongs to the nucleosome assembly protein (NAP) family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q01105-1	1, TAF-I alpha	yes
Q01105-2	2, TAF-I beta
Q01105-3	3
Q01105-4	4

RefSeq proteins (5): NP_001116293, NP_001234929, NP_001234930, NP_001361255, NP_003002* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002164	NAP	Family
IPR037231	NAP-like_sf	Homologous_superfamily

Pfam: PF00956

UniProt features (45 total): modified residue 11, helix 7, region of interest 5, strand 5, sequence variant 4, splice variant 3, turn 3, compositionally biased region 3, initiator methionine 1, chain 1, site 1, cross-link 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
7MTO	X-RAY DIFFRACTION	1.79
2E50	X-RAY DIFFRACTION	2.3
9I15	X-RAY DIFFRACTION	2.47

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q01105-F1	78.62	0.58

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 283–284 (breakpoint for translocation to form set-can oncogene)

Post-translational modifications (12): 2, 7, 28, 63, 68, 146, 150, 172, 154, 11, 15, 24

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-2299718	Condensation of Prophase Chromosomes
R-HSA-450520	HuR (ELAVL1) binds and stabilizes mRNA
R-HSA-1640170	Cell Cycle
R-HSA-450531	Regulation of mRNA stability by proteins that bind AU-rich elements
R-HSA-68875	Mitotic Prophase
R-HSA-68886	M Phase
R-HSA-69278	Cell Cycle, Mitotic
R-HSA-8953854	Metabolism of RNA

MSigDB gene sets: 448 (showing top): MORF_MTA1, GOBP_NEGATIVE_REGULATION_OF_NEURON_APOPTOTIC_PROCESS, MORF_SMC1L1, GCM_MSN, PAL_PRMT5_TARGETS_UP, GCM_NPM1, MORF_UBE2I, MORF_HDAC1, MORF_UBE2N, MORF_RAD21, HSIAO_HOUSEKEEPING_GENES, THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN, LANG_MYB_FAMILY_TARGETS, MORF_HDAC2, USF_C

GO Biological Process (5): DNA replication (GO:0006260), nucleosome assembly (GO:0006334), nucleosome disassembly (GO:0006337), negative regulation of neuron apoptotic process (GO:0043524), negative regulation of DNA-templated transcription (GO:0045892)

GO Molecular Function (6): DNA binding (GO:0003677), chromatin binding (GO:0003682), protein phosphatase inhibitor activity (GO:0004864), protein phosphatase regulator activity (GO:0019888), histone binding (GO:0042393), protein binding (GO:0005515)

GO Cellular Component (9): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), endoplasmic reticulum (GO:0005783), lipid droplet (GO:0005811), cytosol (GO:0005829), protein-containing complex (GO:0032991), perinuclear region of cytoplasm (GO:0048471)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Mitotic Prophase	1
Regulation of mRNA stability by proteins that bind AU-rich elements	1
Metabolism of RNA	1
M Phase	1
Cell Cycle, Mitotic	1
Cell Cycle	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
cytoplasm	3
nucleosome organization	2
binding	2
phosphoprotein phosphatase activity	2
intracellular membrane-bounded organelle	2
DNA metabolic process	1
DNA biosynthetic process	1
chromatin organization	1
protein-DNA complex assembly	1
protein-DNA complex disassembly	1
negative regulation of apoptotic process	1
regulation of neuron apoptotic process	1
neuron apoptotic process	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
nucleic acid binding	1
phosphatase inhibitor activity	1
protein phosphatase regulator activity	1
phosphatase regulator activity	1
protein phosphatase binding	1
protein binding	1
chromosome	1
nuclear lumen	1
intracellular anatomical structure	1
endomembrane system	1
intracellular membraneless organelle	1
cellular_component	1

Protein interactions and networks

STRING

2214 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SET	ANP32A	P39687	991
SET	PPP2CA	P05323	898
SET	NME1	P15531	864
SET	GZMA	P12544	826
SET	APEX1	P27695	755
SET	SETBP1	Q9Y6X0	688
SET	LGMN	Q99538	684
SET	CIP2A	Q8TCG1	632
SET	SGO2	Q562F6	595
SET	AGAP2	Q99490	588
SET	DEK	P35659	572
SET	KMT2A	Q03164	568
SET	HMGB2	P26583	553
SET	H1-0	P07305	540
SET	TAF1	P21675	534

IntAct

196 interactions, top by confidence:

A	B	Type	Score
SET	THAP7	psi-mi:“MI:0915”(physical association)	0.810
THAP7	SET	psi-mi:“MI:0915”(physical association)	0.810
SET	THAP7	psi-mi:“MI:0403”(colocalization)	0.810
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
SET	RAC1	psi-mi:“MI:0915”(physical association)	0.680
RAC1	SET	psi-mi:“MI:0915”(physical association)	0.680
SET	RAC1	psi-mi:“MI:0407”(direct interaction)	0.680
SET	RAC1	psi-mi:“MI:0403”(colocalization)	0.680
FAM111B	SET	psi-mi:“MI:0915”(physical association)	0.670
REPIN1	IPO8	psi-mi:“MI:0914”(association)	0.640
SET	UBTF	psi-mi:“MI:0915”(physical association)	0.640
UBTF	SET	psi-mi:“MI:0915”(physical association)	0.640
UBTF	SET	psi-mi:“MI:0407”(direct interaction)	0.640
SET	TBP	psi-mi:“MI:0915”(physical association)	0.630
TBP	SET	psi-mi:“MI:0915”(physical association)	0.630
SET	TAF1C	psi-mi:“MI:0915”(physical association)	0.630

BioGRID (412): SET (Affinity Capture-MS), SET (Two-hybrid), SET (Two-hybrid), THAP7 (Two-hybrid), FAM111B (Two-hybrid), SET (Reconstituted Complex), THAP7 (Two-hybrid), SET (Co-fractionation), SET (Co-fractionation), VPS72 (Co-fractionation), SET (Affinity Capture-MS), ELAVL1 (Affinity Capture-Western), SET (Affinity Capture-MS), SET (Affinity Capture-MS), SET (Affinity Capture-MS)

ESM2 similar proteins: G3V9R8, O35381, O43423, O60812, O77768, O88978, P07910, P0DME0, P19600, P39687, P49911, P50503, P51122, P97822, Q01105, Q1RMR5, Q28XE2, Q32KP2, Q3SZC6, Q4KLJ8, Q4R3F0, Q5F4A3, Q5RA82, Q5REE1, Q5UAK0, Q5XIE0, Q5ZKT9, Q5ZLF0, Q5ZMN0, Q63945, Q64G17, Q6A1I3, Q6NUW5, Q6P1U7, Q6PAF6, Q7ZUP0, Q7ZY40, Q86X45, Q8AVC1, Q8HY67

Diamond homologs: A0A494C1R9, A2ZX50, A6NKD2, B8AEC1, B8B2R4, B8B4K9, B9FU45, F4JEI8, O19110, O59797, O88852, P0CV98, P0CV99, P0CW00, P0CW01, P0DME0, P53997, P78920, Q01105, Q01534, Q0P5N2, Q18240, Q5R5G8, Q5VND6, Q63945, Q69JW2, Q69ZB3, Q70Z17, Q70Z18, Q70Z19, Q7TQI8, Q86VY4, Q8N831, Q8VD63, Q94K07, Q9BE64, Q9CA59, Q9EQU5, Q9H0U9, Q9H2G4

SIGNOR signaling

8 interactions.

A	Effect	B	Mechanism
GZMA	down-regulates	SET	cleavage
SET	down-regulates	PPP2CA	binding
SET	down-regulates	PPP2CB	binding
SETBP1	up-regulates	SET	binding
CLN8	“down-regulates activity”	SET	binding
PIK3CG	“up-regulates activity”	SET	phosphorylation
PRKD2	“down-regulates activity”	SET	phosphorylation
SET	down-regulates	NME1	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 188 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Ovarian tumor domain proteases	8	17.1×	2e-05
Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells	5	13.7×	1e-03
Positive epigenetic regulation of rRNA expression	5	13.3×	1e-03
RAF activation	5	12.9×	1e-03
RNA Polymerase I Transcription Termination	5	12.6×	2e-03
Cyclin A/B1/B2 associated events during G2/M transition	5	11.9×	2e-03
Regulation of TP53 Degradation	5	11.3×	2e-03
RNA Polymerase I Promoter Clearance	5	11.3×	2e-03

GO biological processes:

GO term	Partners	Fold	FDR
response to antibiotic	5	22.2×	9e-04
positive regulation of miRNA transcription	6	11.0×	4e-03
regulation of apoptotic process	12	6.3×	3e-04
DNA damage response	14	4.7×	8e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

125 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	22
Likely pathogenic	15
Uncertain significance	44
Likely benign	19
Benign	4

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1344907	NM_003011.4(SET):c.458C>A (p.Ser153Ter)	Pathogenic
2499108	NM_003011.4(SET):c.488_489del (p.Gly163fs)	Pathogenic
3160560	NM_003011.4(SET):c.452del (p.Pro151fs)	Pathogenic
3317680	NM_003011.4(SET):c.599del (p.Gly200fs)	Pathogenic
3392539	NM_003011.4(SET):c.442_443del (p.Ser148fs)	Pathogenic
4540565	NM_003011.4(SET):c.106_109del (p.Asp36fs)	Pathogenic
4540568	NM_003011.4(SET):c.77_78del (p.Lys26fs)	Pathogenic
4540569	NM_003011.4(SET):c.328_332del (p.Val110fs)	Pathogenic
4540570	NM_003011.4(SET):c.493-3_504del	Pathogenic
4540571	NM_003011.4(SET):c.644dup (p.Asn215fs)	Pathogenic
4540572	NM_003011.4(SET):c.639G>A (p.Trp213Ter)	Pathogenic
4540573	NM_003011.4(SET):c.729_732del (p.Glu243fs)	Pathogenic
4755524	NM_003011.4(SET):c.493-1G>A	Pathogenic
560208	NM_003011.4(SET):c.650_651dup (p.Gln218fs)	Pathogenic
560209	NM_003011.4(SET):c.660_662del (p.Tyr220_Leu221delinsTer)	Pathogenic
807681	NM_003011.4(SET):c.418_419del (p.Ser140fs)	Pathogenic
817064	NM_003011.4(SET):c.185_186del (p.Lys62fs)	Pathogenic
817338	NM_003011.4(SET):c.78_81del (p.Lys26fs)	Pathogenic
830789	NC_000009.12:g.(?128683896)(128689655_?)del	Pathogenic
860686	NM_003011.4(SET):c.663+5G>C	Pathogenic
986988	NM_003011.4(SET):c.615_619del (p.Glu206fs)	Pathogenic
992875	NM_003011.4(SET):c.663+1G>C	Pathogenic
1691608	NM_003011.4(SET):c.263A>G (p.Asn88Ser)	Likely pathogenic
2500283	NM_003011.4(SET):c.219del (p.Glu73fs)	Likely pathogenic
2505260	NM_003011.4(SET):c.138dup (p.Glu47Ter)	Likely pathogenic
3254904	NM_003011.4(SET):c.103_104del (p.His34_Ile35insTer)	Likely pathogenic
4077497	NM_003011.4(SET):c.193C>T (p.Gln65Ter)	Likely pathogenic
4540567	NM_003011.4(SET):c.314A>G (p.His105Arg)	Likely pathogenic
4819992	NM_003011.4(SET):c.707A>G (p.Asp236Gly)	Likely pathogenic
4819995	NM_003011.4(SET):c.493-3T>A	Likely pathogenic

SpliceAI

1056 predictions. Top by Δscore:

Variant	Effect	Δscore
9:128689654:AGGTG:A	donor_loss	1.0000
9:128689655:GGTG:G	donor_loss	1.0000
9:128689657:T:A	donor_loss	1.0000
9:128691166:GCA:G	acceptor_loss	1.0000
9:128691167:CA:C	acceptor_loss	1.0000
9:128691168:A:AG	acceptor_gain	1.0000
9:128691169:G:GA	acceptor_gain	1.0000
9:128691169:GA:G	acceptor_gain	1.0000
9:128691169:GAA:G	acceptor_gain	1.0000
9:128691169:GAAA:G	acceptor_gain	1.0000
9:128691169:GAAAA:G	acceptor_gain	1.0000
9:128691205:G:GT	donor_gain	1.0000
9:128691223:GACAG:G	donor_gain	1.0000
9:128691224:ACAG:A	donor_loss	1.0000
9:128691226:AGGTA:A	donor_loss	1.0000
9:128691227:GGTAA:G	donor_loss	1.0000
9:128691228:GTA:G	donor_loss	1.0000
9:128691229:T:A	donor_loss	1.0000
9:128691847:A:AG	acceptor_gain	1.0000
9:128691847:ATTT:A	acceptor_gain	1.0000
9:128691848:T:G	acceptor_gain	1.0000
9:128691856:A:AG	acceptor_gain	1.0000
9:128691857:G:GA	acceptor_gain	1.0000
9:128691857:GA:G	acceptor_gain	1.0000
9:128691857:GAC:G	acceptor_gain	1.0000
9:128691857:GACT:G	acceptor_gain	1.0000
9:128691857:GACTT:G	acceptor_gain	1.0000
9:128692654:T:TA	acceptor_gain	1.0000
9:128692655:G:A	acceptor_gain	1.0000
9:128692659:TAGTG:T	acceptor_loss	1.0000

AlphaMissense

1884 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:128691212:A:C	Q52P	1.000
9:128691213:A:C	Q52H	1.000
9:128691213:A:T	Q52H	1.000
9:128691223:G:C	D56H	1.000
9:128691224:A:T	D56V	1.000
9:128691860:T:C	L58P	1.000
9:128691864:T:A	N59K	1.000
9:128691864:T:G	N59K	1.000
9:128691871:G:C	A62P	1.000
9:128691872:C:A	A62D	1.000
9:128691884:T:A	I66N	1.000
9:128691884:T:C	I66T	1.000
9:128691884:T:G	I66S	1.000
9:128691887:T:C	L67S	1.000
9:128691895:G:A	E70K	1.000
9:128691896:A:T	E70V	1.000
9:128691897:A:C	E70D	1.000
9:128691897:A:T	E70D	1.000
9:128691899:A:C	Q71P	1.000
9:128691904:T:C	Y73H	1.000
9:128691904:T:G	Y73D	1.000
9:128691916:C:A	R77S	1.000
9:128691917:G:C	R77P	1.000
9:128691937:A:T	R84W	1.000
9:128691938:G:C	R84T	1.000
9:128691938:G:T	R84M	1.000
9:128691939:G:C	R84S	1.000
9:128691939:G:T	R84S	1.000
9:128691967:T:C	F94L	1.000
9:128691968:T:C	F94S	1.000

dbSNP variants (sampled 300 via entrez): RS1000019030 (9:128693270 T>C), RS1000237440 (9:128688698 C>A,T), RS1000769611 (9:128692119 T>C,G), RS1000952604 (9:128681482 T>C), RS1001139496 (9:128684110 C>T), RS1001192486 (9:128689249 G>A,C), RS1001193718 (9:128693046 T>C), RS1001223589 (9:128689335 C>T), RS1001375203 (9:128693256 C>T), RS1001661172 (9:128693440 T>C), RS1002196298 (9:128690035 G>A,C), RS1002230880 (9:128690209 G>A), RS1002328041 (9:128687339 G>A), RS1002546084 (9:128685335 T>A), RS1002621010 (9:128685809 A>C)

Disease associations

OMIM: gene MIM:600960 | disease phenotypes: MIM:618106, MIM:114550

GenCC curated gene-disease

Disease	Classification	Inheritance
intellectual disability, autosomal dominant 58	Definitive	Autosomal dominant
autosomal dominant non-syndromic intellectual disability	Supportive	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
intellectual disability	Definitive	AD

Mondo (5): intellectual disability, autosomal dominant 58 (MONDO:0020847), hepatocellular carcinoma (MONDO:0007256), dysgerminoma (MONDO:0003002), intellectual disability (MONDO:0001071), autosomal dominant non-syndromic intellectual disability (MONDO:0015802)

Orphanet (2): Hepatocellular carcinoma (Orphanet:88673), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

41 total (30 of 41 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000023	Inguinal hernia
HP:0000154	Wide mouth
HP:0000176	Submucous cleft hard palate
HP:0000218	High palate
HP:0000252	Microcephaly
HP:0000297	Facial hypotonia
HP:0000307	Pointed chin
HP:0000316	Hypertelorism
HP:0000324	Facial asymmetry
HP:0000331	Short chin
HP:0000358	Posteriorly rotated ears
HP:0000400	Macrotia
HP:0000431	Wide nasal bridge
HP:0000455	Broad nasal tip
HP:0000486	Strabismus
HP:0000494	Downslanted palpebral fissures
HP:0000678	Dental crowding
HP:0000750	Delayed speech and language development
HP:0000954	Single transverse palmar crease
HP:0001249	Intellectual disability
HP:0001250	Seizure
HP:0001252	Hypotonia
HP:0001263	Global developmental delay
HP:0001348	Brisk reflexes
HP:0001357	Plagiocephaly
HP:0001382	Joint hypermobility
HP:0001611	Hypernasal speech
HP:0002311	Incoordination
HP:0002465	Poor speech

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST001959_7	Eating disorders (purging via substances)	5.000000e-06
GCST002115_14	Axial length	6.000000e-06
GCST005951_65	Body mass index	5.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0005318	axial length measurement
EFO:0004340	body mass index

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D006528	Carcinoma, Hepatocellular	C04.557.470.200.025.255; C04.588.274.623.160; C06.301.623.160; C06.552.697.160
D004407	Dysgerminoma	C04.557.465.330.300
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295798 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

1 potent at pChembl≥5 of 1 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.52	IC50	30	nM	MOLIBRESIB

PubChem BioAssay actives

1 with measured affinity, of 8 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2178941: Inhibition of SET (unknown origin) incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	ic50	0.0300	uM

CTD chemical–gene interactions

71 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, affects cotreatment, affects expression	4
Cadmium Chloride	increases expression, decreases expression	3
bisphenol F	increases expression, affects cotreatment, decreases expression	2
bisphenol S	increases expression, affects cotreatment, decreases expression	2
Cisplatin	increases response to substance, increases expression	2
Estradiol	affects localization, affects cotreatment, decreases expression	2
Lipopolysaccharides	affects expression, affects response to substance, decreases expression, decreases reaction, increases expression	2
Tretinoin	affects reaction, decreases expression, increases expression, affects expression, affects cotreatment (+1 more)	2
Valproic Acid	affects expression, decreases expression	2
aristolochic acid I	decreases expression	1
berzosertib	affects localization, affects reaction	1
FR900359	affects phosphorylation	1
9-hydroxyoctadecadienoic acid	decreases expression	1
bufotalin	decreases expression	1
alpha phellandrene	decreases expression	1
titanium dioxide	decreases phosphorylation	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, decreases expression	1
trichostatin A	affects cotreatment, increases expression	1
arsenite	affects localization, affects reaction, increases phosphorylation	1
mono-(2-ethylhexyl)phthalate	increases expression	1
sodium arsenite	decreases expression	1
cobaltous chloride	decreases expression	1
tetrabromobisphenol A	increases expression	1
perfluorooctanoic acid	decreases expression	1
coumarin	increases phosphorylation	1
leptomycin B	affects localization, affects reaction, decreases reaction	1
benzyloxycarbonylleucyl-leucyl-leucine aldehyde	decreases expression	1
CD 437	decreases expression	1
chloropicrin	affects expression	1
U 0126	affects cotreatment, increases cleavage	1

ChEMBL screening assays

8 unique, capped per target: 8 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4118953	Binding	Binding affinity to SET in human NCI-H358 cells at 1 uM by mass spectrometry based pull down assay	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_1380	Loucy	Cancer cell line	Female
CVCL_1833	MEGAL	Cancer cell line	Female
CVCL_E0WR	Ubigene K-562 SET KO	Cancer cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00168987	PHASE4	COMPLETED	Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors
NCT00554905	PHASE4	UNKNOWN	Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma
NCT00555334	PHASE4	UNKNOWN	Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma
NCT00556803	PHASE4	UNKNOWN	TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma
NCT00557024	PHASE4	UNKNOWN	Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma
NCT00646100	PHASE4	COMPLETED	Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
NCT00768157	PHASE4	UNKNOWN	Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma
NCT00834860	PHASE4	UNKNOWN	Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma
NCT01098760	PHASE4	COMPLETED	Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients
NCT01102335	PHASE4	UNKNOWN	Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy
NCT01203787	PHASE4	COMPLETED	Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
NCT01298284	PHASE4	UNKNOWN	A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol
NCT01332669	PHASE4	COMPLETED	Drug-eluting Bead in Hepatocellular Carcinoma
NCT01351194	PHASE4	UNKNOWN	Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm
NCT01409499	PHASE4	COMPLETED	Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)
NCT01415063	PHASE4	UNKNOWN	Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma
NCT01438437	PHASE4	UNKNOWN	Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis
NCT01451658	PHASE4	UNKNOWN	A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC)
NCT01570075	PHASE4	UNKNOWN	Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria
NCT01575574	PHASE4	COMPLETED	Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis
NCT01639703	PHASE4	COMPLETED	Hepatic Xenetix-CT Perfusion
NCT01798160	PHASE4	COMPLETED	Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).
NCT01806740	PHASE4	TERMINATED	DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC
NCT01849588	PHASE4	TERMINATED	HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)
NCT01894269	PHASE4	UNKNOWN	Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication
NCT01970748	PHASE4	UNKNOWN	Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices
NCT01997957	PHASE4	UNKNOWN	A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC
NCT02174575	PHASE4	WITHDRAWN	Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery
NCT02253511	PHASE4	UNKNOWN	A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma
NCT02399033	PHASE4	UNKNOWN	Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After Hepatectomy
NCT02472249	PHASE4	COMPLETED	Pharmacological Manipulation of Intrahepatic Arterial Blood Flow in HCC
NCT02504983	PHASE4	UNKNOWN	Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma
NCT02525380	PHASE4	UNKNOWN	Safety and Efficacy of Doxorubicin-eluting-bead Embolization in Patients With Advanced Hepatocellular Carcinoma
NCT02534961	PHASE4	UNKNOWN	Prophylactic Antibiotics Before RFA for HCC
NCT02535117	PHASE4	UNKNOWN	Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent HCC
NCT02729506	PHASE4	UNKNOWN	Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma
NCT02733809	PHASE4	UNKNOWN	Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma
NCT02785380	PHASE4	NOT_YET_RECRUITING	Laparoscopic Surgery VS RFA for Recurrent HCC
NCT02959359	PHASE4	WITHDRAWN	DAA in the Risk of Recurrence After Curative Treatment of HCC
NCT02961998	PHASE4	COMPLETED	Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail